Oral KRAS G12D Inhibitor VS-7375 Achieves 50% Confirmed Response Rate in Second-Line Pancreatic Cancer

The oral KRAS G12D inhibitor VS-7375 showed a confirmed objective response rate of 50% (4/8) in second-line pancreatic ductal adenocarcinoma in the phase 1/2 TARGET-D 101 study. Across second-line and later patients, confirmed ORR was 41% (9/22), with two complete responses, one confirmed. Among 48 patients on 900 mg once daily monotherapy, 2% discontinued due to adverse events and grade 3 treatment-related adverse events occurred in 10%, with no clinically meaningful cumulative toxicity observed.